Rezera's ruvonoflast NLRP3 inhibitor met primary endpoint in RESOLVE-1 trial, reducing hsCRP across cardiometabolic patients.

Mindera Health partners with University of Pennsylvania to investigate quinacrine's mechanism in treatment-resistant ...

UpDoc secures $9.2 million ARPA-H funding to develop autonomous heart failure AI system for FDA authorization. Read the ...

ViaNautis Bio secures SCI Ventures investment to advance polyNaut platform for chronic spinal cord injury treatment. Discover the breakthrough.

FDA grants accelerated approval to Bayer's Hyrnuo (sevabertinib) as first-line therapy for HER2-mutated NSCLC. Learn about ...

Roche's Enspryng receives FDA priority review for MOGAD treatment. First potential therapy for rare autoimmune disease with no approved treatments.

Lotus Neuro debuts focused ultrasound platform to enhance CNS drug delivery to the brain. Discover how this breakthrough technology addresses drug ...

Tempus AI secures $9.5M federal funding to build autonomous heart failure AI agent. Discover how AI is transforming ...

Disc Medicine's anti-TMPRSS6 antibody DISC-3405 significantly reduces phlebotomy needs in polycythemia vera Phase II trial.

McGill and Mount Sinai researchers discover PRMT7 suppresses CD8+ T cell expansion, offering new cancer immunotherapy targets ...

FDA places partial clinical hold on Biohaven's opakalim epilepsy drug. Impact on pivotal trial timeline and SK Biopharmaceuticals deal revealed.

NeOnc Technologies secures $15M funding to advance Phase II CNS cancer programs following NEO100 efficacy readout. Learn more ...